Ask AI
ProCE Banner Activity

Patient–HCP Communication Checklist: CDK4/6 Inhibitor Therapy in Early-Stage Hormone Receptor–Positive/HER2-Negative Breast Cancer

PDF

Download this resource for your patients to provide guidance for communication to ensure consistent and comprehensive counseling while undergoing treatment with CDK4/6 inhibitors for early-stage HR+/HER2- breast cancer.

Released: September 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC. in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

Disclosure

Primary Author

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Atkis Oncology, Artios, Arvinas, AstraZeneca, Avenzo, Bayer, BeOne, Bicycle, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celcuity, Samsung Bioepis, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Summit, Sumitovant Biopharma, Tango, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Merck, Menarini/Stemline, NanoString, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvinas, Gilead, Jazz, Lilly, Pfizer, Roche.